Fig. 1From: Molecular correlation of response to pyrotinib in advanced NSCLC with HER2 mutation: biomarker analysis from two phase II trialsStudy design and treatment efficacy of enrolled patients. a Key eligibility criteria and study design. b Kaplan–Meier estimates of PFS for enrolled patients. c Best response of enrolled patients. d Concordance analysis of high-frequency mutations in paired plasma and tumor tissue samples among 21 patients. e Correlation between mutation frequencies plasma samples versus tissue samples. PFS progression free survival, PR partial response, SD stable disease, PD progressive disease, NA not availableBack to article page